Opdivo, Yervoy combo demonstrates activity in patients with dMMR, MSI-H mCRC
Bristol-Myers Squibb announced new data from a cohort of the phase 2 CheckMate -142 trial evaluating Opdivo and Yervoy for the treatment of patients with DNA mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer. With a median of 13.4 months of follow-up, the primary endpoint of objective response rate per investigator assessment was 55%. Responses were durable, with median duration of response not yet reached and 94% of responses ongoing at time of data cutoff. The overall survival rate at one year was 85%, and median OS was not yet reached. Grade 3-4 treatment-related adverse events occurred in 32% of patients receiving the Opdivo plus Yervoy combination. Patients received mCRC combination dosing of Opdivo plus Yervoy every three weeks for four doses, followed by Opdivo every two weeks until disease progression, death or unacceptable toxicity.